Literature DB >> 24225851

Chronic arsenic exposure and microbial drug resistance.

Malcolm J McConville1, Stuart A Ralph.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24225851      PMCID： PMC3856794          DOI： 10.1073/pnas.1319659110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  21 in total

Review 1.  One century of arsenic exposure in Latin America: a review of history and occurrence from 14 countries.

Authors:  Jochen Bundschuh; Marta I Litter; Faruque Parvez; Gabriela Román-Ross; Hugo B Nicolli; Jiin-Shuh Jean; Chen-Wuing Liu; Dina López; María A Armienta; Luiz R G Guilherme; Alina Gomez Cuevas; Lorena Cornejo; Luis Cumbal; Regla Toujaguez
Journal:  Sci Total Environ       Date:  2011-09-29       Impact factor: 7.963

2.  Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.

Authors:  Maya Berg; Manu Vanaerschot; Andris Jankevics; Bart Cuypers; Ilse Maes; Sandip Mukherjee; Basudha Khanal; Suman Rijal; Syamal Roy; Fred Opperdoes; Rainer Breitling; Jean-Claude Dujardin
Journal:  Mol Microbiol       Date:  2013-09-11       Impact factor: 3.501

3.  Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.

Authors:  Budhaditya Mukherjee; Rupkatha Mukhopadhyay; Bijoylaxmi Bannerjee; Sayan Chowdhury; Sandip Mukherjee; Kshudiram Naskar; Uday Sankar Allam; Dipshikha Chakravortty; Shyam Sundar; Jean-Claude Dujardin; Syamal Roy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-22       Impact factor: 11.205

4.  Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.

Authors:  Meghan R Perry; Susan Wyllie; Andrea Raab; Joerg Feldmann; Alan H Fairlamb
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

5.  Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use.

Authors:  Shyam Sundar; Anup Singh; Madhukar Rai; Vijay K Prajapati; Avinash K Singh; Bart Ostyn; Marleen Boelaert; Jean-Claude Dujardin; Jaya Chakravarty
Journal:  Clin Infect Dis       Date:  2012-05-09       Impact factor: 9.079

6.  Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.

Authors:  Maria Adelaida Gómez; Adriana Navas; Ricardo Márquez; Laura Jimena Rojas; Deninson Alejandro Vargas; Victor Manuel Blanco; Roni Koren; Dan Zilberstein; Nancy Gore Saravia
Journal:  J Antimicrob Chemother       Date:  2013-08-24       Impact factor: 5.790

7.  Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?

Authors:  Meghan R Perry; Susan Wyllie; Vijay Kumar Prajapati; Joerg Feldmann; Shyam Sundar; Marleen Boelaert; Alan H Fairlamb
Journal:  PLoS Negl Trop Dis       Date:  2011-09-27

8.  Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden.

Authors:  Manu Vanaerschot; Simonne De Doncker; Suman Rijal; Louis Maes; Jean-Claude Dujardin; Saskia Decuypere
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

9.  Treatment of visceral leishmaniasis: model-based analyses on the spread of antimony-resistant L. donovani in Bihar, India.

Authors:  Anette Stauch; Hans-Peter Duerr; Jean-Claude Dujardin; Manu Vanaerschot; Shyam Sundar; Martin Eichner
Journal:  PLoS Negl Trop Dis       Date:  2012-12-20

Review 10.  Management of trypanosomiasis and leishmaniasis.

Authors:  Michael P Barrett; Simon L Croft
Journal:  Br Med Bull       Date:  2012-11-07       Impact factor: 4.291
View more
  2 in total

1.  Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.

Authors:  M A Collier; K J Peine; S Gautam; S Oghumu; S Varikuti; H Borteh; T L Papenfuss; A R Sataoskar; E M Bachelder; K M Ainslie
Journal:  Int J Pharm       Date:  2016-01-05       Impact factor: 5.875

2.  Coenzyme Q10 protected against arsenite and enhanced the capacity of 2,3-dimercaptosuccinic acid to ameliorate arsenite-induced toxicity in mice.

Authors:  Victoria K Mwaeni; James N Nyariki; Ngalla Jillani; George Omwenga; Mathew Ngugi; Alfred Orina Isaac
Journal:  BMC Pharmacol Toxicol       Date:  2021-04-07       Impact factor: 2.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.